Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

计划入组 30 人 · 首次发布于 2025 年 12 月 2 日

Converting HR+ Breast Cancer Into an Individualized Vaccine

计划入组 100 人 · 首次发布于 2019 年 1 月 15 日

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

计划入组 50 人 · 首次发布于 2012 年 3 月 22 日

Fulvestrant(Faslodex, Fulvestrant Mylan)

C₃₂H₄₇F₅O₃S · Rx

Ribociclib(Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali)

C₂₃H₃₀N₈O · Rx

Breast cancer (BreakBio)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

Dual mTORC1/2 Inhibitor BI 860585 Shows Promise in Phase I Breast Cancer Trial

Relay Therapeutics' RLY-2608: A Mutant-Selective PI3Kα Inhibitor Enters Phase I Trials for HR+/HER2- Breast Cancer

Triple-Drug Therapy Doubles Survival Time in Advanced Breast Cancer with PIK3CA Mutation